Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 6:15:1488345.
doi: 10.3389/fimmu.2024.1488345. eCollection 2024.

Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy

Xiaoyan Qi  1   2 , Cheng Cheng  1   3 , Dawei Zhang  1   4 , Zongjiang Yu  5 , Xiangwei Meng  1   6
Affiliations

Exploring the synergy between tumor microenvironment modulation and STING agonists in cancer immunotherapy

Xiaoyan Qi et al. Front Immunol. .
No abstract available

Keywords: STING agonists; cancer immunotherapy; immune suppression; macrophage polarization; tumor microenvironment (TME).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Schematic illustration of the TME and the STING pathway, and their synergy. The TME consists of various components including tumor cells, macrophages (TAMs, with M1 and M2 phenotypes), regulatory Tregs, MDSCs, and ECM. The STING pathway is activated by cytosolic DNA, leading to the production of IFNs and activation of DCs and T cells. The synergy between TME modulation (such as reprogramming TAMs from M2 to M1, and targeting MDSCs) and STING agonists is shown, with arrows indicating the interactions and effects on immune responses and tumor cells.
See this image and copyright information in PMC

References

    1. Colley A, Brauns T, Sluder AE, Poznansky MC, Gemechu Y. Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy. Trends Mol Med. (2024) 30:765–80. doi: 10.1016/j.molmed.2024.05.001 - DOI - PubMed
    1. Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. (2022) 19:254–67. doi: 10.1038/s41571-022-00600-w - DOI - PMC - PubMed
    1. Zemek RM, Anagnostou V, Pires da Silva I, Long GV, Lesterhuis WJ. Exploiting temporal aspects of cancer immunotherapy. Nat Rev Cancer. (2024) 24:480–97. doi: 10.1038/s41568-024-00699-2 - DOI - PubMed
    1. Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, et al. . Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. (2023) 14:1167975. doi: 10.3389/fimmu.2023.1167975 - DOI - PMC - PubMed
    1. Li Y, Xiang S, Pan W, Wang J, Zhan H, Liu S. Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective. Front Oncol. (2023) 13:1166860. doi: 10.3389/fonc.2023.1166860 - DOI - PMC - PubMed

LinkOut - more resources